Additionally, GLP-1 analog treatment is known reduce the adipocyte hormone leptin (Larsen et al., 2001; Iepsen et al., 2015), a pro-inflammatory hormone that is elevated in MS patients and in EAE where a reduction in leptin is protective (Matarese et al., 2010). The gene discussed is GCG; the disease is myeloid sarcoma.